Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clinical Genomics
North Ryde, New South Wales, Australianiaid.nih.gov ↗
- Ownership
- Private
- Employees
- ~61
- Development stage
- Commercial
01
Overview
Clinical Genomics has developed a sensitive blood-based test for colorectal cancer recurrence monitoring based on methylated DNA from BCAT1 and IKZF1 genes. The company also offers the InSure® FIT™ fecal immunochemical test for non-invasive CRC screening. These products are validated, FDA registered, TGA licensed, and NATA accredited[3][5].
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic testMolecular diagnostic assay (methylated DNA markers)Device (fecal immunochemical test)
- Industry
- Molecular Diagnostics
02
Partnerships
Quest Diagnostics[2]
Beyond the preview
Go deeper on Clinical Genomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clinical Genomics.